Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery

Reviewed

From BiognosysReviewed by Maria OsipovaJul 24 2020

Biognosys announced today that it started working together with Boehringer Ingelheim. Here, Biognosys and Boehringer Ingelheim will team up to expand next-generation proteomics applications in drug discovery programs at Boehringer Ingelheim.

Image Credit: Shuttertock/ranjith ravindran

As a proof-of-concept, the companies perform comprehensive proteome profiling of a preclinical mouse model of idiopathic pulmonary fibrosis (IPF) to gain new insights into the disease biology. Using Biognosys’ single-shot HRM/DIA mass spectrometry, over 8’000 proteins can be quantified across a large number of lung tissue samples. The data will serve as a rich resource for the development of novel therapeutic strategies.

This collaboration is a great example of how proteomics technologies are becoming essential tools in drug discovery programs. We are committed to working closely with Boehringer Ingelheim to make discovery proteomics an integral part of preclinical research."

Dr. Oliver Rinner, CEO at Biognosys.

The initial focus of the activities will be on applications for fibrotic diseases. Boehringer Ingelheim also plans to implement the single-shot HRM/DIA capability in-house, using Biognosys’ Spectronaut™ software.

Source:

Boehringer Ingelheim and Biognosys Join Forces on Applying Quantitative Proteomics Tools in Drug Discovery - Biognosys

Posted in: Drug Discovery & Pharmaceuticals | Life Sciences News

Tags: Drug Discovery, Fibrosis, Idiopathic Pulmonary Fibrosis, Mass Spectrometry, Mouse Model, Preclinical, Proteome, Proteomics, Pulmonary Fibrosis, Research, Software, Spectrometry

Comments (0)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

APA
Biognosys. (2021, December 06). Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx.
MLA
Biognosys. "Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx>.
Chicago
Biognosys. "Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery". News-Medical. https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx. (accessed November 21, 2024).
Harvard
Biognosys. 2021. Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx.